The Global Congenital Adrenal Hyperplasia Market is expected to grow at a CAGR of ~7.1 % during the forecast period 2017-2023.
Congenital adrenal hyperplasia is an inherited genetic disorder affects the adrenal glands. The patient suffering from these disorders lacks CAH enzymes which help in the production of hormones that help regulate metabolism, the immune system, blood pressure and other essential physiological functions.
These disorders most commonly occur in children and infants. A number of the diagnostic tests are available in the market for the diagnosis of these disorders. According to the National Institute of Child Health and Human Development (2015), about one in 18,000 children suffer from congenital adrenal hyperplasia each year. The global congenital adrenal hyperplasia market is majorly driven by the increasing prevalence of the disorder, unmet needs for the treatment of the genetic disorders and rising demand for better and effective medicines for the treatment.
Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4946 .
The risk of these disorders increases in the patients with the history of any genetic disease. Additionally, during last decade, the number of the patient suffering from genetic disorders across the globe has elevated. Government are stared supporting the research institutes and manufacturers for research & development to introduce the better treatment for the genetic disorders. Moreover, increasing government support and rapid developments in technology have fueled the growth of the market. The absolute treatment of congenital adrenal hyperplasia is not available in the market. High cost of the treatment and unavailability of precise treatment may slow the growth of the market.
Some of key the players in the market are Neurocrine Biosciences, Inc. (U.S.), Fusion IP plc (U.K), Novartis AG (Switerzland), Mitsubishi Chemical Holdings Corporation (Japan), Johnson & Johnson (U.S.), GlaxoSmithKline Plc (U.S.), Cadila healthcare (India), Sanofi (France), Macleods Pharmaceuticals (India), GlaxoSmithKline Plc. (U.K), Allergan (Ireland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Merck & Co., Inc. (U.S.)
The Americas dominate the global congenital adrenal hyperplasia market owing to the increasing number of patients with congenital adrenal hyperplasia, and genetic disorders. Due to rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better drugs. Additionally, well-developed technology, high healthcare expenditure, and strong government support for research & development have fueled the growth of the market in this region.
Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/4946 .
Europe commands the second largest market for congenital adrenal hyperplasia which is followed by Asia Pacific. Availability of funds, increasing need for better treatment options and strong government support drive the growth of the market in Europe. Germany, France & U.K holds the major share in the Europe market.
Asia Pacific is the fastest growing congenital adrenal hyperplasia market owing to the increasing number of patients suffering from genetic disorders and presence of a huge opportunity for the development of the market. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market.
- Brief TOC
- Report Prologue
- Market Introduction
- Research Methodology
- Market Dynamics
- Market Factor Analysis
- Global Congenital Adrenal Hyperplasia Market, by Type
- Global Congenital Adrenal Hyperplasia Market, by Diagnosis & Treatment
- Global Congenital Adrenal Hyperplasia Market, by End User
- Global Congenital Adrenal Hyperplasia Market, by Region
- Company Landscape
- Company Profiles
Ask to Expert @ https://www.marketresearchfuture.com/enquiry/4946 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312